Gilead Sciences Inc. has terminated the collaboration and license agreement with the Company and its rights to GS-4774 have been returned to GlobeImmune. The company has terminated the lease for 40,000 gross square feet of office, laboratory and manufacturing space which formerly served as the company's corporate headquarters.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 5 | |
-1.62% | 103B | |
+7.43% | 101B | |
+4.40% | 23.07B | |
-12.00% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.83% | 16.94B | |
+6.41% | 14.07B | |
+37.78% | 12.35B |
- Stock Market
- Equities
- GBIM Stock
- News GlobeImmune, Inc.
- Gilead Sciences, Inc. Terminates the Collaboration and License Agreement with GlobeImmune